Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTT3: AM-101 for Acute Peripheral Tinnitus
2012-004099-20Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Sep 2013
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tinnitus comparing AM-101 intratympanic injections with Placebo intratympanic injections (2 arms). Started Sep 2013; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on 2012-004099-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004099-20.